Project Details
Abstract
Among the metastatic forms of prostate adenocarcinoma (PCa) are those that express
neuroendocrine (NE) markers, often referred to as neuroendocrine differentiation (NED) or
NE phenotype. NED is seen in >30% of PCa and is associated with poor prognosis and
androgen independence. By comparing expression profiles of human primary prostate cancer
biopsies and androgen refractory metastatic prostate cancer biopsies, we discovered that the
expression of activin A is increased in PCa patients with metastatic propensity and correlates
with increased PSA expression, and Gleason scores. We further found that NE-like cells,
whether they were trans-differentiated from human PCa cell line or human PCa biopsies after
androgen deprivation therapy (ADT), express high level of activin A. More interestingly, it
was further discovered that the neurite outgrowth of these cells was significantly increased
upon activin A treatment with androgen blockade, suggesting a stimulatory role of activin A
in their NED. This finding led us to a big challenge since most current ADT of PCa are
targeting inhibition of androgen receptor (AR) signaling and it is expected that targeting AR
can kill differentiated luminal epithelial cells that comprises still the majority of refractory
tumors, but it would allow small population of NE cells that expand higher potential of tumor
malignancy. It led us to realize that the failure of ADT might be due to this fact and a
development of better understanding of NE tumor formation and strategy to target NE
population cells is essential. Therefore, we hypothesize that activin A signaling is required
for the formation of PCa with NE phenotype and targeting activin A pathway combined
with ADT may eventually block occurrence and growth of hormone refractory PCa. In
order to prove our hypothesis, we propose three aims as follows:
Aim 1: Use two in vivo mouse models to investigate the roles of activin A on the
formation of PCa with NE tumor. First, we will use TRAMP/activin A-conditional KO
mice and the transgenic mice expressing probasin-activin βA generated by our lab and
examine the NED foci numbers and tumor incidence to prove the roles of activin A in NE
tumor formation. Next, the localization and expression level of active forms of FoxA2/Smads
proteins will be correlated with NE markers in PCa tumor to determine whether activin
A/FoxA2/Smads pathways are activated in prostate NE tumor.
Aim 2: To study the mechanisms of FoxA2/Smads signaling-mediated transcriptional
programs that are required for activin A-associated NED in PCa. First, we will study
whether disruption of Smads/FoxA2 function may affect NED by analyzing NE outgrowth
assay and NE markers expression. Next, we will identify a subset of activin A-mediated
targeted genes, which are cooperatively regulated by FoxA2/Smads. We will also determine
whether MAP-1B gene and identified target genes coregulated by Smads/FoxA2 are essential
for activin A-associated NE phenotype of prostate cancer cells.
Aim 3: To investigate whether ADT allows activation of activin A signaling to stimulate
neuroendocrine cell differentiation and inhibit epithelial cell growth in prostate cancer.
We will use more PCa cell lines and in vivo mouse models to confirm androgen blockade
promote activin A function in stimulation of neuroendocrine cell differentiation and
suppression of epithelial cell growth in PCa. More importantly, we will evaluate the effects of
the combined therapy of ADT and activin A inhibitors on blocking occurrence and growth of
hormone refractory PCa tumors.
Impact: Identification of activin A signaling pathways mediated with NE tumor formation
could provide the potential targets for novel hormone refractory PCa therapy. Successful
accomplishment of this study will shed new light to battle PCa that ADT therapy alone
cannot.
Project IDs
Project ID:PC10301-0140
External Project ID:NSC102-2628-B182-004-MY3
External Project ID:NSC102-2628-B182-004-MY3
Status | Finished |
---|---|
Effective start/end date | 01/08/14 → 31/07/15 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.